These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 19540857

  • 1. Pharmacological characterization of senktide-induced tail whips.
    Nordquist RE, Ballard TM, Algeyer B, Pauly-Evers M, Ozmen L, Spooren W.
    Neuropharmacology; 2010 Jan; 58(1):259-67. PubMed ID: 19540857
    [Abstract] [Full Text] [Related]

  • 2. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
    Nordquist RE, Durkin S, Jacquet A, Spooren W.
    Eur J Pharmacol; 2008 Dec 14; 600(1-3):87-92. PubMed ID: 18930726
    [Abstract] [Full Text] [Related]

  • 3. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
    Sundqvist M, Kristensson E, Adolfsson R, Leffler A, Ahlstedt I, Engberg S, Drmota T, Sigfridsson K, Jussila R, de Verdier J, Novén A, Johansson A, Påhlman I, von Mentzer B, Lindström E.
    Eur J Pharmacol; 2007 Dec 22; 577(1-3):78-86. PubMed ID: 17920583
    [Abstract] [Full Text] [Related]

  • 4. Bronchoconstrictor effect of the tachykinin NK₃-receptor agonists [MePhe⁷]-neurokinin B and senktide in the isolated guinea pig lung.
    Corboz MR, Rivelli MA, Eckel SP.
    Exp Lung Res; 2010 Nov 22; 36(9):509-21. PubMed ID: 20939761
    [Abstract] [Full Text] [Related]

  • 5. Localization and function of NK(3) subtype tachykinin receptors of layer V pyramidal neurons of the guinea-pig medial prefrontal cortex.
    Simmons MA, Sobotka-Briner CD, Medd AM.
    Neuroscience; 2008 Oct 28; 156(4):987-94. PubMed ID: 18801417
    [Abstract] [Full Text] [Related]

  • 6. Neurokinin 3 receptor activation potentiates the psychomotor and nucleus accumbens dopamine response to cocaine, but not its place conditioning effects.
    Jocham G, Lauber AC, Müller CP, Huston JP, de Souza Silva MA.
    Eur J Neurosci; 2007 Apr 28; 25(8):2457-72. PubMed ID: 17445241
    [Abstract] [Full Text] [Related]

  • 7. Neurokinin A and senktide attenuate scopolamine-induced impairment of spontaneous alternation performance in mice.
    Ukai M, Shinkai N, Kameyama T.
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Jun 28; 16(3):97-101. PubMed ID: 8905797
    [Abstract] [Full Text] [Related]

  • 8. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G, Butini S, Fattorusso C, Catalanotti B, Gemma S, Nacci V, Morelli E, Cagnotto A, Mereghetti I, Mennini T, Carli M, Minetti P, Di Cesare MA, Mastroianni D, Scafetta N, Galletti B, Stasi MA, Castorina M, Pacifici L, Vertechy M, Di Serio S, Ghirardi O, Tinti O, Carminati P.
    J Med Chem; 2004 Jan 01; 47(1):143-57. PubMed ID: 14695828
    [Abstract] [Full Text] [Related]

  • 9. Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonist.
    Sarau HM, Griswold DE, Bush B, Potts W, Sandhu P, Lundberg D, Foley JJ, Schmidt DB, Webb EF, Martin LD, Legos JJ, Whitmore RG, Barone FC, Medhurst AD, Luttmann MA, Giardina GA, Hay DW.
    J Pharmacol Exp Ther; 2000 Oct 01; 295(1):373-81. PubMed ID: 10992004
    [Abstract] [Full Text] [Related]

  • 10. Characterization of RO4583298 as a novel potent, dual antagonist with in vivo activity at tachykinin NK₁ and NK₃ receptors.
    Malherbe P, Knoflach F, Hernandez MC, Hoffmann T, Schnider P, Porter RH, Wettstein JG, Ballard TM, Spooren W, Steward L.
    Br J Pharmacol; 2011 Feb 01; 162(4):929-46. PubMed ID: 21039418
    [Abstract] [Full Text] [Related]

  • 11. In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.
    Dawson LA, Langmead CJ, Dada A, Watson JM, Wu Z, de la Flor R, Jones GA, Cluderay JE, Southam E, Murkitt GS, Hill MD, Jones DN, Davies CH, Hagan JJ, Smith PW.
    Eur J Pharmacol; 2010 Feb 10; 627(1-3):106-14. PubMed ID: 19879867
    [Abstract] [Full Text] [Related]

  • 12. Cardiovascular and behavioural effects of intracerebroventricularly administered tachykinin NK3 receptor antagonists in the conscious rat.
    Cellier E, Barbot L, Regoli D, Couture R.
    Br J Pharmacol; 1997 Oct 10; 122(4):643-54. PubMed ID: 9375960
    [Abstract] [Full Text] [Related]

  • 13. Characterization of behavioral response to amphetamine, tyrosine hydroxylase levels, and dopamine receptor levels in neurokinin 3 receptor knockout mice.
    Nordquist RE, Savignac H, Pauly-Evers M, Walker G, Knoflach F, Borroni E, Glaentzlin P, Bohrmann B, Messer J, Ozmen L, Albientz A, Spooren W.
    Behav Pharmacol; 2008 Sep 10; 19(5-6):518-29. PubMed ID: 18690106
    [Abstract] [Full Text] [Related]

  • 14. Interaction of the tachykinin NK3 receptor agonist senktide with behavioral effects of cocaine in marmosets (Callithrix penicillata).
    de Souza Silva MA, Mello EL, Müller CP, Jocham G, Maior RS, Huston JP, Tomaz C, Barros M.
    Peptides; 2006 Sep 10; 27(9):2214-23. PubMed ID: 16621146
    [Abstract] [Full Text] [Related]

  • 15. Discovery of a novel class of selective non-peptide antagonists for the human neurokinin-3 receptor. 2. Identification of (S)-N-(1-phenylpropyl)-3-hydroxy-2-phenylquinoline-4-carboxamide (SB 223412).
    Giardina GA, Raveglia LF, Grugni M, Sarau HM, Farina C, Medhurst AD, Graziani D, Schmidt DB, Rigolio R, Luttmann M, Cavagnera S, Foley JJ, Vecchietti V, Hay DW.
    J Med Chem; 1999 Mar 25; 42(6):1053-65. PubMed ID: 10090788
    [Abstract] [Full Text] [Related]

  • 16. NK(3) receptor agonism promotes episodic-like memory in mice.
    Zlomuzica A, Dere E, Huston JP, de Souza Silva MA.
    Neurobiol Learn Mem; 2008 Sep 25; 90(2):420-5. PubMed ID: 18556225
    [Abstract] [Full Text] [Related]

  • 17. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
    Rumsey WL, Aharony D, Bialecki RA, Abbott BM, Barthlow HG, Caccese R, Ghanekar S, Lengel D, McCarthy M, Wenrich B, Undem B, Ohnmacht C, Shenvi A, Albert JS, Brown F, Bernstein PR, Russell K.
    J Pharmacol Exp Ther; 2001 Jul 25; 298(1):307-15. PubMed ID: 11408556
    [Abstract] [Full Text] [Related]

  • 18. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
    Cirillo R, Astolfi M, Conte B, Lopez G, Parlani M, Sacco G, Terracciano R, Fincham CI, Sisto A, Evangelista S, Maggi CA, Manzini S.
    Neuropeptides; 2001 Jul 25; 35(3-4):137-47. PubMed ID: 11884203
    [Abstract] [Full Text] [Related]

  • 19. Vasopressin release from the rat hypothalamo-neurohypophysial system: effects of tachykinin NK-1 and NK-2 receptors agonists and antagonists.
    Juszczak M.
    Neuro Endocrinol Lett; 2005 Aug 25; 26(4):367-72. PubMed ID: 16136007
    [Abstract] [Full Text] [Related]

  • 20. Pharmacological characterization of the behavioural syndrome induced by the NK-3 tachykinin agonist senktide in rodents: evidence for mediation by endogenous 5-HT.
    Stoessl AJ, Dourish CT, Iversen SD.
    Brain Res; 1990 May 28; 517(1-2):111-6. PubMed ID: 1695859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.